InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.
OBJECTIVES Baseline systemic inflammation has emerged as a determinant of outcome after CD19-directed CAR-T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B-cell lymphoma (LBCL) receiving commerci...